Abstract
Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Current Vascular Pharmacology
Title: Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Volume: 8 Issue: 4
Author(s): Kosmas I. Paraskevas, Gabriel Karatzas, Alkisti Pantopoulou, Dimitrios G. Iliopoulos and Despina Perrea
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Abstract: Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Export Options
About this article
Cite this article as:
I. Paraskevas Kosmas, Karatzas Gabriel, Pantopoulou Alkisti, G. Iliopoulos Dimitrios and Perrea Despina, Targeting Dyslipidemia in the Metabolic Syndrome: An Update, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330861
DOI https://dx.doi.org/10.2174/157016110791330861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidyslipidemic Capacity of <i>Cleome arabica</i> (L.) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design Carbon Nanotube-Based Electrochemical Biosensing Platforms: Fundamentals,Applications, and Future Possibilities
Recent Patents on Biotechnology Functional Polymeric Nano/Microparticles for Surface Adsorption and Delivery of Protein and DNA Vaccines
Current Drug Delivery Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Causes of Impaired Fertility in Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Modulation of MMP-9 Pathway by Lycopene in Macrophages and Fibroblasts Exposed to Cigarette Smoke
Inflammation & Allergy - Drug Targets (Discontinued) Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Autologous Cell Therapy for Vascular Regeneration: The Role of Proangiogenic Cells
Current Medicinal Chemistry The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases
Current Molecular Medicine An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Use of Medication in Coronary Imaging by CT
Current Medical Imaging The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued)